Isai Peimer on Clubhouse

Bio

Public/private biotech investing at Surveyor Capital (Citadel)
2016-present

Select private financings:

2022:
Avenzo, Ambagon, ImmPACT Bio, Remix

2021:
Led Ventyx, Acelyrin, Quanta, Aura

Also participated in Solve Tx, Affinivax (acquired by GSK), Nimbus (acquired by Takeda), Verve, Design, Artiva, DTx Pharma, OnKure Therapeutics, AN2 Therapeutics, Vanqua Bio, Icosavax, Janux Therapeutcs, Gennao Bio, Zentera, Vigil, Attralus, Anjarium, Expansion Tx

2020:
Led financing of VelosBio (acquired by MRK), Dyne, Enliven and Talaris

Also participated in Neuron23, Korro, Imago (acquired by MRK), VectivBio, Olema, Kinnate, Immuneering, Vera, Bioshin (acquired by Biohaven/Pfizer), Scorpion, Aerovate

2019: Zentalis, Prevail (acquired by LLY), Satsuma

Previous board director at Ambit Biosciences (acquired by Daiichi), Adheron (acquired by Roche), Xencor, Inotek (merged with RCKT), and Corridor Pharma (acquired by AZN)

Former Managing Director of MedImmune Ventures (AstraZeneca’s investment fund)
2010-2016

Visium Asset Management / Bernstein
2008-2010

Started my career at Merck & Co as a chemist and switched to investing via strategy consulting and investment banking (JPMorgan)
1998-2008

MBA @ Tuck School (Dartmouth)
Chemistry @ Emory

NYC & Berkshires
Married with two kids


Connect off CH at LinkedIn-> http://linkedin.com/in/isai-peimer-66b1a41

***My views are my own and do not reflect the views of my employer or affiliates.